Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form of COVID-19

{ 'institution': [{'name': 'medRxiv'}], 'indexed': {'date-parts': [[2024, 3, 1]], 'date-time': '2024-03-01T23:10:30Z', 'timestamp': 1709334630492}, 'posted': {'date-parts': [[2020, 7, 3]]}, 'group-title': 'Infectious Diseases (except HIV/AIDS)', 'reference-count': 8, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2020, 9, 16]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>Due to the constantly growing numbers of COVID-19 ' 'infections and death cases attempts were undertaken to find drugs with anti SARS-CoV-2 ' 'activity among ones already approved for other pathologies. In the framework of such ' 'attempts, in a number of in vitro, as well as in vivo, models it was shown that ' 'hydroxychloroquine (HCQ) has an effect against SARS-CoV-2. While there was not enough ' 'clinical data to support the use of HCQ, several countries including Russia have included HCQ ' 'in treatment protocols for infected patients and for prophylactic. Here, we evaluated the ' 'SARS-CoV-2 RNA in nasopharynx swabs from infected patients in mild conditions and compared ' 'the viral RNA load dynamics between patients receiving HCQ and control group without ' 'antiviral pharmacological therapy. We found statistically significant relationship between ' 'maximal RNA quantity and patients’ deteriorating medical conditions, as well as confirmed the ' 'arterial hypertension to be a risk factor for people with COVID-19. However, we showed that ' 'HCQ therapy neither shortened the viral shedding period nor reduced the virus RNA ' 'load.</jats:p>', 'DOI': '10.1101/2020.06.30.20143289', 'type': 'posted-content', 'created': {'date-parts': [[2020, 7, 3]], 'date-time': '2020-07-03T16:42:12Z', 'timestamp': 1593794532000}, 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form of ' 'COVID-19', 'prefix': '10.1101', 'author': [ {'given': 'Alexey', 'family': 'Komissarov', 'sequence': 'first', 'affiliation': []}, {'given': 'Ivan', 'family': 'Molodtsov', 'sequence': 'additional', 'affiliation': []}, {'given': 'Oxana', 'family': 'Ivanova', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elena', 'family': 'Maryukhnich', 'sequence': 'additional', 'affiliation': []}, {'given': 'Svetlana', 'family': 'Kudryavtseva', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alexey', 'family': 'Mazus', 'sequence': 'additional', 'affiliation': []}, {'given': 'Evgeniy', 'family': 'Nikonov', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elena', 'family': 'Vasilieva', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'reference': [ { 'key': '2021021207400923000_2020.06.30.20143289v2.1', 'doi-asserted-by': 'crossref', 'first-page': '732', 'DOI': '10.1093/cid/ciaa237', 'article-title': 'In vitro antiviral activity and projection of optimized dosing design ' 'of hydroxychloroquine for the treatment of severe acute respiratory ' 'syndrome coronavirus 2 (sars-cov-2)', 'volume': '71', 'year': '2020', 'journal-title': 'Clinical infectious diseases: an official publication of the Infectious ' 'Diseases Society of America.'}, { 'key': '2021021207400923000_2020.06.30.20143289v2.2', 'doi-asserted-by': 'crossref', 'first-page': '16', 'DOI': '10.1038/s41421-020-0156-0', 'article-title': 'Hydroxychloroquine, a less toxic derivative of chloroquine, is ' 'effective in inhibiting sars-cov-2 infection in vitro', 'volume': '6', 'year': '2020', 'journal-title': 'Cell discovery.'}, { 'key': '2021021207400923000_2020.06.30.20143289v2.3', 'doi-asserted-by': 'crossref', 'first-page': '101735', 'DOI': '10.1016/j.tmaid.2020.101735', 'article-title': 'Therapeutic use of chloroquine and hydroxychloroquine in covid-19 and ' 'other viral infections: A narrative review', 'volume': '35', 'year': '2020', 'journal-title': 'Travel medicine and infectious disease.'}, { 'key': '2021021207400923000_2020.06.30.20143289v2.4', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(20)30113-4'}, { 'key': '2021021207400923000_2020.06.30.20143289v2.5', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc2001737'}, { 'key': '2021021207400923000_2020.06.30.20143289v2.6', 'doi-asserted-by': 'crossref', 'first-page': '793', 'DOI': '10.1093/cid/ciaa345', 'article-title': 'Quantitative detection and viral load analysis of sars-cov-2 in ' 'infected patients', 'volume': '71', 'year': '2020', 'journal-title': 'Clinical infectious diseases: an official publication of the Infectious ' 'Diseases Society of America.'}, { 'key': '2021021207400923000_2020.06.30.20143289v2.7', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/SO140-6736(20)30566-3'}, { 'key': '2021021207400923000_2020.06.30.20143289v2.8', 'doi-asserted-by': 'crossref', 'first-page': '824', 'DOI': '10.1038/s41440-020-0485-2', 'article-title': 'Covid-19 patients with hypertension have more severe disease: A ' 'multicenter retrospective observational study', 'volume': '43', 'year': '2020', 'journal-title': 'Hypertension Research.'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2020.06.30.20143289', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 12, 15]], 'date-time': '2021-12-15T15:07:17Z', 'timestamp': 1639580837000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2020.06.30.20143289'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 7, 3]]}, 'references-count': 8, 'URL': 'http://dx.doi.org/10.1101/2020.06.30.20143289', 'relation': { 'is-preprint-of': [ { 'id-type': 'doi', 'id': '10.1371/journal.pone.0246396', 'asserted-by': 'subject'}]}, 'published': {'date-parts': [[2020, 7, 3]]}, 'subtype': 'preprint'}